Twist Bioscience Corp. (TWST)

Over the past six months, Twist Bioscience's stock has been influenced by several events, including the release of fiscal Q2 and Q3 2025 earnings reports. Analyst ratings have generally been positive, with a consensus of 'Buy' and an average 12-month price target of $48.56. Insider trading activity has primarily involved sales by company officers. Institutional investors have shown mixed activity, with some increasing their holdings and others decreasing or acquiring new positions. An investor rights law firm has announced an investigation into whether certain officers and directors of Twist Bioscience breached their fiduciary duties.

Publicly available information directly detailing the demand seasonality for Twist Bioscience's products and services is not readily available in the provided search results. Specific insights into the seasonal demand patterns for Twist Bioscience's offerings were not found.

Twist Bioscience is a synthetic biology company focused on manufacturing and selling synthetic DNA-based products, operating within the Healthcare sector, specifically in the Diagnostics & Research and Biotechnology: Biological Products industries. The company's core business revolves around its silicon-based DNA synthesis platform, enabling high-throughput, cost-effective production of synthetic DNA. Its major products include synthetic genes and gene fragments used in various applications such as therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and academic research. The company also offers Oligo pools for targeted Next-Generation Sequencing (NGS), CRISPR gene editing, and mutagenesis experiments, as well as NGS target enrichment solutions. Furthermore, Twist Bioscience provides immunoglobulin G proteins and antibody libraries for drug discovery and development, and explores DNA as a digital data storage medium.

Twist Bioscience Corporation is headquartered in South San Francisco, California, and the majority of its revenue is derived from the United States.

Within the past year, there have been no specific negative events that have significantly impacted Twist Bioscience's brand reputation. In previous years, the company has been recognized as a 'Great Place to Work-Certified™ company,' one of the 'Most Innovative Biotech Companies,' and listed among the 'Fast 500 Technology Companies.' The ongoing investigation by an investor rights law firm could potentially have reputational implications.

Twist Bioscience Corporation's stock ownership is a mix of institutional, retail, and individual investors. Institutional investors hold a significant portion of the company's shares. Major institutional owners include ARK Investment Management LLC, BlackRock Inc., Vanguard Group Inc., Artisan Partners Limited Partnership, William Blair Investment Management, Llc, State Street Corp, EdgePoint Investment Group Inc., and Invesco Ltd. ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG) are also significant holders. Ever Alpha Fund LP is noted as a large individual shareholder. Individual insiders hold approximately 1.69% of the shares.